Mereo BioPharma Reports Q3 2026 Financial Results, Highlights setrusumab and alvelestat progress
Mereo reported $26.1 million in cash available through late-2027 despite ongoing late-stage clinical program challenges. The company provided updates on regulatory pathways for setrusumab in osteogenesis imperfecta and alvelestat in alpha-1 antitrypsin deficiency.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed